Sarepta Therapeutics Announces Second Quarter 2021 Financial Results and Recent Corporate Developments 8421 Sarepta announces successful completion of endofphase2 meeting for SRP9001 microdystrophin with FDAs Office of Tissues and Advanced Therapies OTAT and plans to initiate pivotal trial SRP9001301 Study 301 or EMBARK in September of 2021 Net product sales for the second quarter of 2021 reached 1418 million a 27 increase over the same quarter of prior year In light of its overperformance Sarepta raises its fullyear product revenue guidance by nearly 30 million to between 565 million to 575 million CAMBRIDGE Mass Aug 04 2021 GLOBE NEWSWIRE  Sarepta Therapeutics Inc NASDAQSRPT the leader in precision genetic medicine for rare diseases today reported financial results for the second quarter of 2021